Key Takeaways Regarding Use of 45 Gy Novel Radiotherapy in CNS CancersMay 31st 2023
Rupesh Kotecha, MD, discusses the key findings from an analysis centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.
COSMIC-313 and Role of Triplet Regimens in Frontline Setting in Advanced RCCMay 30th 2023
A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.
Recent Trials Change Practice for Newly Diagnosed Multiple MyelomaMay 25th 2023
Prerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently based on clinical trial outcomes.
Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCLMay 23rd 2023
Hun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
IO-IO Regimens in Advanced RCC: Recent Data UpdatesMay 23rd 2023
Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.